Hereditary Angioedema (HAE) Therapeutics

Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS10974
Available Format:
Pages: 105

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation


Hereditary angioedema (HAE) is a disease characterized by repeated incidents of swelling (angioedema). The physical signs of the disease include, non-inflammatory swelling of the skin and mucous membrane, that occurs to the subcutaneous tissue in face, arms, buttocks and genitals, and abdominal organs such as stomach, bladder, and urethra. In most of the cases, patients reported that the episodes of swelling worsen over a period of 12 to 24 hours, and usually resolve within 72 hours. The symptoms can persist for up to five days, with the migration of swelling to different sites. It has been observed that the disease is generally unresponsive to antihistamines.


HAE Therapeutics Pipeline Analysis

There are many pharmaceutical companies that are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as a single agent therapy. They also allow the development of specific targeted therapies with better drug delivery. For instance, Ionis Pharmaceuticals, Inc. has developed an antisense technology which is efficient and enables the company to create a robust pipeline of antisense drugs to treat patients. Some of the features for the development of the drugs with the help of this technology include, selectively targeted therapy, and less accumulation of drugs in kidneys, liver, and other digestive organs. The rationale for the development of technology is to make available the cost-effective therapies for the treatment to the patients suffering of HAE.

Pipeline Analysis

As of November 2017, the HAE therapeutics pipeline comprises of 20 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry